Curated News
By: NewsRamp Editorial Staff
June 11, 2026

Helus Pharma's CMO to Speak at H.C. Wainwright Neuro Conference

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Helus Pharma's Phase 3 drug HLP003 with Breakthrough Therapy designation offers a competitive edge in the $12B depression market.
  • Helus Pharma develops proprietary serotonergic agonists (NSAs) to activate serotonin pathways and promote neuroplasticity for mental health.
  • Helus Pharma's novel treatments aim to provide durable relief for millions suffering from depression and anxiety, improving lives.
  • Helus Pharma's CMO will present at H.C. Wainwright Neuro Perspectives Conference on June 15, 2026, with on-demand access.

Impact - Why it Matters

This news matters because Helus Pharma is at the forefront of developing novel treatments for mental health conditions like depression and anxiety, which affect millions worldwide. The fireside chat at a prestigious conference signals growing investor and industry interest in their NSA pipeline, particularly HLP003 and HLP004, which could offer more effective and durable therapies. For patients and healthcare providers, successful development of these drugs could mean improved outcomes and new options for those who do not respond to existing treatments.

Summary

Helus Pharma, the commercial operating name of Cybin Inc. (NASDAQ: HELP) (Cboe CA: HELP), is set to make a significant splash at the upcoming H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The clinical-stage pharmaceutical company announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat during the conference, which takes place June 15-16, 2026. The session will be available on demand starting June 15 at 7:00 a.m. EDT, offering investors and industry watchers a unique opportunity to gain insights into Helus Pharma's innovative pipeline of novel serotonergic agonists (NSAs).

Helus Pharma is dedicated to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. With class-leading data, the company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Currently, Helus Pharma is advancing HLP003, an NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder, and the company has an extensive research portfolio of investigational NSAs. The fireside chat will likely highlight these promising therapies and their potential to transform the mental health treatment landscape.

This news was disseminated by MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. MissionIR focuses on assisting IR firms with syndicated content to enhance visibility for companies like Helus Pharma. For those looking to stay informed about the latest developments, the full press release is available at https://ibn.fm/KsnJW, and investor updates can be found at Helus Pharma newsroom.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma's CMO to Speak at H.C. Wainwright Neuro Conference

blockchain registration record for this content.